Adults who had mild COVID-19 symptoms for no longer than 3 days and had the disease confirmed by real-time polymerase chain reaction (RT-PCR) or an antigen test SARS-CoV-2 COVID-19 upper respiratory tract fingerroot silver nanoparticles
Conditions
Interventions
If the patient is willing to participate in the study, the following intervention will be performed on all patients:
1. Specimen collection by nasal swab at the left and right noses
2. Administration
Experimental Drug
FR-Bio-AgNP nasal spray
Sponsors
National Research Council of Thailand (NRCT)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age: at least 18 years old 2. COVID-19 was diagnosed by RT-PCR or an antigen test within 24 hours or within 3 days of the onset of symptoms 3. Mild COVID-19 symptoms 4. Willingness to take part in the current research 5. The SARS-CoV-2 RT-PCR cycle threshold is not more than 25
Exclusion criteria
Exclusion criteria: 1. Allergy to silver or fingerroot 2. Pregnancy or lactation 3. Severe COVID-19 symptoms 4. Receiving antiviral treatment for COVID-19 before enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral culture 30 minutes after administration Cytopathic effect, Plaque titration | — |
Secondary
| Measure | Time frame |
|---|---|
| Viral culture 4 hours after administration Cytopathic effect, Plaque titration,RT-PCR 30 minutes after administration Ct value,RT-PCR 4 hours after administration Ct value,Safety Administration, 30 minutes, 4 hours, 24 hours, 7 days after administration Adverse reactions,Silver level Baseline, 4 hours, 7 days after administration Blood and urine tests | — |
Countries
Thailand
Contacts
Public ContactAmorn Leelarasamee
Thai Biomedical Engineering Research Association
Outcome results
None listed